Novartis and DNDi to jointly develop a new oral drug to treat visceral leishmaniasis

(Drugs for Neglected Diseases Initiative) Novartis and the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development (R&D) organization, have signed a collaboration and licence agreement to jointly develop LXE408, as a potential new oral treatment for visceral leishmaniasis, one of the world's leading parasitic killers.